middle.news
Aroa Biosurgery Surpasses FY26 Targets with NZ$104m Revenue and Eyes FY27 Growth
8:48am on Tuesday 26th of May, 2026 AEST
•
Healthcare
Read Story
Aroa Biosurgery Surpasses FY26 Targets with NZ$104m Revenue and Eyes FY27 Growth
8:48am on Tuesday 26th of May, 2026 AEST
Key Points
FY26 revenue NZ$103.9m, 23% growth
Myriad sales jump 54%, driving growth
Normalised EBITDA triples to NZ$12.6m
Symphony trial meets primary endpoint
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Aroa Biosurgery (ASX:ARX)
OPEN ARTICLE